May 2026

Global Lyme Alliance Symposium

TNX-4800: A Long-Acting, Bactericidal, Human Monoclonal Antibody to Prevent Lyme Disease in the U.S.

May 2026

AAPA 2026

Treatment with TNX-102 SL (CBP SL) Produces Clinically Meaningful Improvements in Patient-Centered Outcomes in Fibromyalgia

Pharmacokinetic Characterization of Tonmya^® (TNX-102 SL), a Sublingual Formulation of Cyclobenzaprine (CBP SL) for the Treatment of Adults with Fibromyalgia

Tonmya^® (TNX-102 SL; CBP SL) Steady-State Pharmacokinetics Compared to Oral Simulations

April 2026

4th Annual Ticks and Tickborne Diseases Symposium: TNX-4800 Phase 1 Data and Plans for Adaptive Phase 2 Field Study

April 2026

American Association for Cancer Research (AACR) Annual Meeting 2026: In Vitro Characterization of Fully Human Antagonistic Anti-BTLA Monoclonal Antibodies

April 2026

American Association for Cancer Research (AACR) Annual Meeting 2026: Pharmacokinetics of TNX-1700 in Non-Human Primates and Human FcRn/Serum Albumin Transgenic Mice

March 2026

World Vaccine Conference 2026 — A Long-Acting Monoclonal Antibody for Prevention of Lyme Disease

Mark S. Klempner, MD, UMass Chan Medical School

March 2026

8th International Congress on Controversies in Fibromyalgia Oral Presentations

March 2026

2026 American Academy of Pain Medicine (AAPM) PainConnect Annual Meeting

January 2026

Non-Opioid Pain Therapeutics Summit, Boston MA / 27-29 Jan 2026

October 2025

American College of Rheumatology Convergence Conference 2025, Chicago: TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, Demonstrates Pain Reduction and Favorable Tolerability in Participants With Fibromyalgia